Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Political science’s Karen Beckwith talks about Hilary Clinton’s visibility throughout her career
- Vice Provost of International Affairs David Fleshler talks about connecting with foreign policy officials at RNC
- School of Medicine professor receives two Innovation Grants in pursuit of HIV cure
- Find out how you can make the most of your retirement plan at workshops next week
- University Technology encourages Apple users to update operating systems to address security threat